In vivo demonstration of an antithrombin effect of abciximab

This publication has 8 references indexed in Scilit:

• Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention
  American Heart Journal, 1999
• Administration of Abciximab During Percutaneous Coronary Intervention Reduces Both Ex Vivo Platelet Thrombus Formation and Fibrin Deposition
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1998
• Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
  New England Journal of Medicine, 1997
• Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
  The Lancet, 1997
• In Vitro Effects of the Platelet Glycoprotein IIb/IIIa Receptor Antagonist c7E3 Fab on the Activated Clotting Time
  Circulation, 1997
• Venous activated clotting time after intra-arterial heparin: Effect of site of administration and timing of sampling
  Catheterization and Cardiovascular Diagnosis, 1996
• Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial)
  The American Journal of Cardiology, 1995
• Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
  New England Journal of Medicine, 1994